1700014B07Rik Inhibitors
Chemical inhibitors of 1700014B07Rik can influence the activity of this protein through various mechanisms, each related to the inhibition of specific kinases and signaling pathways. Staurosporine, a broad-spectrum kinase inhibitor, can hinder the activity of 1700014B07Rik by competing with ATP for binding to its active site, a common mechanism for kinase inhibition. Similarly, Bisindolylmaleimide I, as a specific inhibitor of protein kinase C, can disrupt the regulatory phosphorylation events that 1700014B07Rik may undergo, effectively reducing its kinase activity. LY294002 and Wortmannin, both potent inhibitors of phosphoinositide 3-kinases, can alter the PI3K/AKT pathway, leading to reduced activity of downstream proteins, which may include 1700014B07Rik if it is part of this signaling cascade. PD98059 and U0126 target MEK1/2, which are upstream of MAPK/ERK kinases; inhibition here can result in decreased activation of 1700014B07Rik if it is regulated by this pathway. Rapamycin acts upon mTORC1 within the mTOR signaling pathway, and its inhibition can suppress the functions of downstream proteins, potentially including 1700014B07Rik.
Further affecting the activity of 1700014B07Rik, SB203580 can selectively inhibit p38 MAPK, which could decrease the kinase activity of 1700014B07Rik if it is part of the p38 MAPK signaling. PP2, as a selective inhibitor of Src family kinases, can interfere with signaling pathways that 1700014B07Rik may be involved in, particularly if it is regulated by Src kinase-mediated phosphorylation. SP600125's inhibition of JNK from the MAPK family can disrupt processes that govern cellular proliferation, which may include the regulatory functions of 1700014B07Rik. Additionally, ZM-447439 and AZD1152-HQPA target Aurora kinases; the former is a broad inhibitor of these kinases, while the latter is selective for Aurora B kinase. Inhibition of Aurora kinases can disrupt cell cycle progression and mitosis, affecting the activity of 1700014B07Rik if it plays a role in these cellular events governed by Aurora kinase activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent kinase inhibitor known to inhibit a broad spectrum of kinases. As 1700014B07Rik is a kinase, staurosporine can inhibit its activity by binding to its ATP-binding site, thereby preventing the phosphorylation of its substrates. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I, also known as GF 109203X, is a specific inhibitor of protein kinase C (PKC). Since 1700014B07Rik might be regulated by PKC-mediated phosphorylation, inhibition of PKC can result in the reduction of 1700014B07Rik kinase activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, LY294002 can alter signaling pathways that rely on PI3K activity, which can result in the downstream inhibition of 1700014B07Rik if it is part of the PI3K/AKT pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which prevents the activation of MAPK/ERK kinases. Inhibition of this pathway can disrupt the cellular processes that may involve 1700014B07Rik through the MAPK/ERK signaling cascade. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, specifically binding to mTORC1. By inhibiting mTORC1, rapamycin can suppress the mTOR signaling pathway, potentially leading to the inhibition of the 1700014B07Rik function if it is mTOR pathway-dependent. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. Inhibition of p38 MAPK can decrease the activity of downstream kinases and transcription factors that may be crucial for the function of 1700014B07Rik within the p38 MAPK signaling pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family kinases. As Src kinases can influence various signaling pathways, inhibition of these kinases by PP2 could lead to the functional inhibition of 1700014B07Rik if it is part of a Src-dependent signaling process. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which blocks the activation of MAPK/ERK kinases. By inhibiting MEK1/2, U0126 can hinder the phosphorylation and activity of proteins downstream in the ERK pathway that may include 1700014B07Rik. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. By inhibiting PI3K, wortmannin can negatively influence the PI3K/AKT pathway, potentially leading to the inhibition of the 1700014B07Rik function if it operates within this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK family. Inhibiting JNK activity can interfere with signaling pathways that regulate cell proliferation and apoptosis, potentially inhibiting 1700014B07Rik if it is involved in JNK-regulated processes. | ||||||